|Budget Amount *help
¥44,980,000 (Direct Cost: ¥34,600,000、Indirect Cost: ¥10,380,000)
Fiscal Year 2012: ¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2011: ¥14,430,000 (Direct Cost: ¥11,100,000、Indirect Cost: ¥3,330,000)
Fiscal Year 2010: ¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
We have developed novel strategies to induce immunogenic cell death of cancer cells. We have also developed novel strategies to augment anti-tumor immunity by using antibodies activating the immunostimulatory pathways (such as 4-1BB, CD27, and Notch2) and those blocking the immunosuppressive pathways (such as CTLA-4, PD-1, TIM-3) in combination with standard chemotherapy, radiotherapy, and antibody therapy targeting cancer cells.